Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Managing renal failure in patients with multiple myeloma

Efstathios Kastritis • 27 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Bortezomib Carfilzomib Cyclophosphamide Daratumumab Dexamethasone Pomalidomide Selinexor

Efstathios Kastritis, MD, University of Athens, Athens, Greece, proposes treatment and management strategies for patients with multiple myeloma who exhibit renal failure, highlighting the value of incorporating anti-CD38 monoclonal antibodies (mAbs) when treating these patients.This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Efstathios Kastritis

1:45
Treatment options available for patients with AL amyloidosis beyond chemotherapy & transplant
Efstathios Kastritis • 27 Sep 2023
1:04
Treatment approaches for AL amyloidosis versus ATTR amyloidosis
Efstathios Kastritis • 27 Sep 2023
1:30
AL amyloidosis: current and prospective treatments
Efstathios Kastritis • 10 Jun 2023
1:50
Current and emerging treatments for Waldenström's macroglobulinemia
Efstathios Kastritis • 10 Jun 2023

Related Videos

3:55
Overview of the SIRIUS clinical trial in the treatment of multiple myeloma
Maria-Victoria Mateos • 29 Jan 2016
2:35
MRD Focus: why measurable residual disease testing is the future
Bruno Paiva et al. • 16 Aug 2018
10:26
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al. • 14 Jun 2016
1:26
New targets in relapsed/refractory multiple myeloma patients
Sagar Lonial • 22 Jun 2017
The content of VJHemOnc is intended for healthcare professionals